Oncopharmpod

Breakwater, Ensartinib, & SC Nivo

Informações:

Synopsis

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.